Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.94+0.07 (+1.19%)
At close: 04:00PM EST
5.94 0.00 (0.00%)
After hours: 05:39PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.87
Open5.77
Bid5.85 x 800
Ask6.05 x 1400
Day's Range5.77 - 6.18
52 Week Range3.59 - 80.67
Volume498,328
Avg. Volume641,201
Market Cap253.547M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

    NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences: Benzinga Global Small Cap Conference: December 8 – 9, 2021 Dr. Federoff will d

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality

    Company Continues to Secure Resources to Build Gene Editing/Cell Therapy Drug Development PlatformNEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of Susan McClatchey as Vice President, Head of Quality. “We are aggressively p

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition

    NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering by certain selling stockholders of up to 6,281,454 shares of Brooklyn’s common stock received in connection with Brooklyn’s acquisition of Novellus, Inc. in July 2021. Brooklyn will not receive any proceeds from any shares

Advertisement
Advertisement